Prime Day Deal: Yes, the Dyson Supersonic Nural Hair Dryer Is Worth the Hype, and It's $100 Off
I never thought I'd actually own the Dyson Supersonic Nural. This thing had been sitting on my wishlist for months. But I recently received one as a gift, and I'm not being dramatic when I say I let out a gasp when I unwrapped it. It felt like someone had handed me the crown jewels of hair tools. (Thanks, Mom!)
Fast-forward a few months and I can confidently say I'm completely obsessed with it. This isn't one of those luxe gadgets that ends up collecting dust in the back of a closet or drawer. I use it pretty much daily, and every time I do, I think, "Whoa, this really is that good."
Hey, did you know? CNET Deals texts are free, easy and save you money.
How I use my super speedy Dyson hair dryer
Drying my hair used to be a whole production -- arms aching, sweating and annoyed by the end, and still somehow left with frizz and flyaways. Now, it takes me under 10 minutes, which still kind of blows my mind. I have thick, slightly longer than shoulder-length hair that holds onto moisture like it's a job, so this is no small feat.
The Nural model has a cool feature that senses how close it is to your scalp and adjusts the heat automatically. I didn't really get what that meant until I used it. Basically, it stops me from roasting my roots while still drying everything quickly.
The Dyson Supersonic comes with a number of attachments, including a wide-tooth comb, a flyaway attachment, a gentle air attachment and a diffuser.
Macy Meyer/CNET
I usually start with the smoothing nozzle when I want a sleek look, but if I'm feeling lazy or just running late, I'll just rough-dry with no attachment at all. On days when I decide to lean into my natural texture, the diffuser is a game-changer when I scrunch my hair into waves. It doesn't flatten out my curls or make them frizzy like my old dryer did.
It's also a lot quieter than I expected and super lightweight. I've dried my whole head while half-asleep, coffee (or wine if it's the evening) in one hand, Dyson in the other. It really is that easy.
Why the Dyson makes a gasp-worthy gift
Honestly, this is one of those things I never would've bought for myself (hello, price tag), but now that I have it, I can't imagine going back. It's the ultimate "treat yourself" item, but in this case, someone else treated me and I'll never stop being grateful.
If you're looking for a gift that feels luxurious yet practical, this checks all the boxes. Especially now that it's on sale at the lowest price ever. Seriously, now's the time.
My final thoughts
The Dyson Supersonic Nural isn't just hype; it's genuinely made my hair styling better. I don't dread drying my hair anymore. In fact, I kind of enjoy it? Which, for me, is pretty amazing.
If you're on the fence about it or you've been eyeing it forever like I was, this sale might just be the nudge you need.
If you're looking for other fun gifts, here are our favorite kitchen gifts under $50. You can also read my reviews of my favorite Everything Maker, and my favorite coffee and espresso system.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Regeneron Reveals The Regeneron Prize For Creative Innovation 2025 Winners
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) awarded the 13th annual Regeneron Prize for Creative Innovation to early-career biomedical researchers who displayed exceptional innovation. The winners for 2025 are Dr. Alissandra L. Hillis, a postdoctoral fellow at MIT, and Mr. Sreekar Mantena, a Harvard-MIT M.D.-Ph.D. candidate and Broad Institute nominee. Each received an institutional award of $5,000 and $50,000. Copyright: delcreations / 123RF Stock Photo Top U.S. research institutions nominate candidates for the Regeneron Prize to submit 'dream projects' in biomedicine. Dr. Hillis from Professor Matthew Vander Heiden's lab suggested new methods for researching endometriosis. Mr. Mantena, who works under Professor Soumya Raychaudhuri at Brigham and Women's Hospital, wants to investigate thymic decrease with age using single-cell genomics. Seven other finalists earned $5,000 each. The prize has given out close to $2 million since it was established in 2013. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)'s broader STEM programs have reached 3.25 million students worldwide since 2020. While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.
Yahoo
9 minutes ago
- Yahoo
US and China extend trade truce another 90 days, easing tension between world's largest economies
WASHINGTON (AP) — President Donald Trump extended a trade truce with China for another 90 days Monday, at least delaying once again a dangerous showdown between the world's two biggest economies. Trump posted on his Truth Social platform that he signed the executive order for the extension, and that 'all other elements of the Agreement will remain the same.' Beijing at the same time also announced the extension of the tariff pause via the official news agency Xinhua. The previous deadline was set to expire at 12:01 a.m. Tuesday. Had that happened the U.S. could have ratcheted up taxes on Chinese imports from an already high 30%, and Beijing could have responded by raising retaliatory levies on U.S. exports to China. The pause buys time for the two countries to work out some of their differences, perhaps clearing the way for a summit later this year between Trump and Chinese President Xi Jinping, and it has been welcomed by the U.S. companies doing business with China. Sean Stein, president of the U.S.-China Business Council, said the extension is 'critical' to give the two governments time to negotiate a trade agreement that U.S. businesses hope would improve their market access in China and provide the certainty needed for companies to make medium- and long-term plans. 'Securing an agreement on fentanyl that leads to a reduction in U.S. tariffs and a rollback of China's retaliatory measures is acutely needed to restart U.S. agriculture and energy exports,' Stein said. Reaching a pact with China remains unfinished business for Trump, who has already upended the global trading system by slapping double-digit taxes – tariffs – on almost every country on earth. The European Union, Japan and other trading partners agreed to lopsided trade deals with Trump, accepting once unthinkably U.S. high tariffs (15% on Japanese and EU imports, for instance) to ward off something worse. Trump's trade policies have turned the United States from one of the most open economies in the world into a protectionist fortress. The average U.S. tariff has gone from around 2.5% at the start of the year to 18.6%, highest since 1933, according to the Budget Lab at Yale University. But China tested the limits of a U.S. trade policy built around using tariffs as a cudgel to beat concessions out of trading partners. Beijing had a cudgel of its own: cutting off or slowing access to its rare earths minerals and magnets – used in everything from electric vehicles to jet engines. In June, the two countries reached an agreement to ease tensions. The United States said it would pull back export restrictions on computer chip technology and ethane, a feedstock in petrochemical production. And China agreed to make it easier for U.S. firms to get access to rare earths. 'The U.S. has realized it does not have the upper hand,'' said Claire Reade, senior counsel at Arnold & Porter and former assistant U.S. trade representative for China affairs. In May, the U.S. and China had averted an economic catastrophe by reducing massive tariffs they'd slapped on each other's products, which had reached as high as 145% against China and 125% against the U.S. Those triple-digit tariffs threatened to effectively end trade between the United States and China and caused a frightening sell-off in financial markets. In a May meeting in Geneva they agreed to back off and keep talking: America's tariffs went back down to a still-high 30% and China's to 10%. Having demonstrated their ability to hurt each other, they've been talking ever since. 'By overestimating the ability of steep tariffs to induce economic concessions from China, the Trump administration has not only underscored the limits of unilateral U.S. leverage, but also given Beijing grounds for believing that it can indefinitely enjoy the upper hand in subsequent talks with Washington by threatening to curtail rare earth exports,'' said Ali Wyne, a specialist in U.S.-China relations at the International Crisis Group. "The administration's desire for a trade détente stems from the self-inflicted consequences of its earlier hubris.' It's unclear whether Washington and Beijing can reach a grand bargain over America's biggest grievances. Among these are lax Chinese protection of intellectual property rights and Beijing's subsidies and other industrial policies that, the Americans say, give Chinese firms an unfair advantage in world markets and have contributed to a massive U.S. trade deficit with China of $262 billion last year. Reade doesn't expect much beyond limited agreements such as the Chinese saying they will buy more American soybeans and promising to do more to stop the flow of chemicals used to make fentanyl and to allow the continued flow of rare-earth magnets. But the tougher issues will likely linger, and 'the trade war will continue grinding ahead for years into the future,'' said Jeff Moon, a former U.S. diplomat and trade official who now runs the China Moon Strategies consultancy. ____ Associated Press Staff Writer Josh Boak contributed to this story. Paul Wiseman And Didi Tang, The Associated Press
Yahoo
9 minutes ago
- Yahoo
Viking Therapeutics Concludes Broad Manufacturing Agreement With CordenPharma To Support Commercialization of VK2735
Viking Therapeutics, Inc. (NASDAQ:VKTX) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Viking Therapeutics, Inc. (NASDAQ:VKTX) and CordenPharma have concluded a multi-year manufacturing contract to facilitate the commercial production of VK2735, the company's dual GLP-1/GIP agonist for obesity. The deal guarantees a yearly supply of more than 1 billion oral pills, 100 million autoinjectors, 100 million vial/syringe units, and several metric tons of API. Prepayments of $150 million will be made by the firm through 2028 and applied to upcoming orders. The agreement offers specific capacity for both oral and subcutaneous formulations. michaelheim/ Viking Therapeutics, Inc. (NASDAQ:VKTX)'s main metabolic therapy candidate, VK2735, is being developed as an injectable and oral medication. Phase 3 development for the injectable version is scheduled to start in Q2 2025, while the company is now completing a Phase 2 VENTURE-Oral trial. The business still owns global rights to VK2735. CEO Brian Lian noted that CordenPharma's end-to-end supply capability and peptide production experience are essential for growing commercial demand. Viking Therapeutics, Inc. (NASDAQ:VKTX) anticipates that the product will have conventional pharmaceutical margins and have a multibillion-dollar potential. It is among the Best Weight Loss Stocks. While we acknowledge the potential of VKTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.
